CURI CuriosityStream Forecast, Technical & Fundamental Analysis

CURI's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CURI turned positive on September 15, 2026. Looking at past instances where CURI's MACD turned positive, the stock continued to rise in 40 of 46 cases over the following month. The odds of a continued upward trend are 87%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on CURI as a result. In 66 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

CURI moved above its 50-day moving average on September 10, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where CURI advanced for three days, in 170 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 115 of 139 cases where CURI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CURI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.093) is normal, around the industry mean (3.773). CURI's P/E Ratio (1606.560) is considerably higher than the industry average of (153.852). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.299). CURI has a moderately high Dividend Yield (0.115) as compared to the industry average of (0.035). P/S Ratio (2.156) is also within normal values, averaging (8.232).

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. CURI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CURI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.